Leader in Biomolecular Solutions for Life Science

www.abclonal.com

Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein

Catalog No.: RP00282 Recombinant

Sequence Information

Species	Gene ID	Swiss Prot
Human	8795	O14763-1

Tags
C-His

Synonyms
CD262;DR5;KILLER;KILLER/DR5;TRAIL-R2;TRAILR2;TRICK2;TRICK2A;TRICK2B;TRICKB;ZTNFR9;TNFRSF10B

Product Information

Source	Purification
HEK293 cells	≥ 90 % as determined by SDS-PAGE.

Calculated MW	Observed MW
15.13 kDa	15-25 kDa

Endotoxin
< 0.1 EU/μg of the protein by LAL method.

Formulation
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.Contact us for customized product form or formulation.

Reconstitution
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact

400-999-6126

cn.market@abclonal.com.cn

www.abclonal.com.cn

* □□□□□□□□□□□□□□□□□□□□□□□□□□□□□

Background

This protein is a member of the TNF-receptor superfamily, and contains an intracellular death domain. This receptor can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by this protein.

Basic Information

Description
Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein is produced by HEK293 expression system. The target protein is expressed with sequence (Ile 56 - Glu 182) of human DR5 (Accession #NP_003833.3) fused with a 6×His tag at the C-terminus.

Bio-Activity
1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human TRAIL at 2 μg/mL (100 μL/well) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.|2.Measured by its ability to inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED_{50} for this effect is 0.38-1.5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.|3.Measured by its binding ability in a functional ELISA.Immobilized Human TRAIL / TNFSF10 Protein at 2μg/mL (100 μL/well) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.

Shipping
Lyophilized proteins are shipped at ambient temperature.
Liquid proteins are shipped at frozen temperature with dry ice.
Upon receipt, store it immediately at the temperature recommended below.

Storage
Store at -20℃
Avoid repeated freeze/thaw cycles.

Operational Notes
For your safety and health, please wear a lab coat and disposable gloves for handling.

Validation Data



Recombinant Human TNFRSF10B/DR5/TRAIL-R2/CD262 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.



Immobilized Recombinant Human TRAIL at 2μg/mL (100 μL/well) can bind Recombinant Human DR5 with a linear range of 14-56 ng/mL.



Immobilized Human TRAIL / TNFSF10 Protein at 2μg/mL (100 μL/well) can bind Human CD262 Protein with a linear range of 0.5-14.1 ng/mL.



Recombinant Human TNFRSF10B inhibit TRAIL-mediated cytotoxicity using L-929 mouse fibroblast cells treated with TRAIL. The ED_{50} for this effect is 0.38-1.5 pg/mL in the presence of 20 ng/mL Recombinant Human TRAIL/TNFSF10.